Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for cancer patients. Our proprietary platforms and therapeutic candidates help position us to enter potential partnering and licensing arrangements, which may include upfront fees, development milestones, royalties and other compensation. At Aptevo Therapeutics, our core values of ownership?and collaboration—combined with a history of innovation, dedication, and development—are positioning Aptevo Therapeutics to develop the science of what’s next in biotechnology.
Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technologies. As a result, Aptevo has been able to attract some of the most innovative minds in the field. Many of our team members have notable experience with other pioneering biotech companies including ZymoGenetics, Immunex, Dendreon, Pfizer, VLST, MedImmune and more.
The technology behind our success
At Aptevo Therapeutics, next-generation technologies are key to the company’s future. Our highly versatile?ADAPTIR™ and ADAPTIR-FLEX™ platform technologies are designed to engineer products?that have potential to meaningfully improve and extend the lives of patients.
Aptevo’s ADAPTIR and ADAPTIR-FLEX technologies are suitable for producing immunotherapeutics for oncology, hematology, and autoimmune and inflammatory diseases (AIID). These technologies can produce monospecific, bispecific, and multispecific therapeutic molecules, which may have functional advantages over monoclonal antibodies.
It’s the science of what’s next at Aptevo Therapeutics.